Drug Profile
Research programme: age-related macular degeneration - InNexus
Alternative Names: IXS 312; IXSVEGFLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InNexus Biotechnology
- Class Antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Age-related macular degeneration; Retinal dysplasia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Age-related-macular-degeneration in USA (Topical)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Retinal dysplasia in USA (Topical)
- 30 Jun 2010 Preclinical trials in Age-related macular degeneration in USA (unspecified route)